Galmed Pharmaceuticals

^{Priced, Nasdaq: GLMD}

Clinical-stage biotech with a candidate for liver diseases (NASH).

Industry: Health Care

First Day Return: +6.0%

GLMD

Clinical-stage biotech with a candidate for liver diseases (NASH).

IPO News for Galmed Pharmaceuticals

Immunotherapy biotech Tobira Therapeutics sets terms for $60 million IPO; researching HIV and NASH 07/21/14
Immunotherapy biotech Tobira Therapeutics files for a $69 million IPO to treat NASH and HIV 06/23/14
Liver disease biotech Lumena Pharmaceuticals files for a $75 million IPO 04/02/14

IPO Data
IPO Date	03/12/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$38
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.galmedpharma.com
Headquarters	Tel Aviv, Israel
Founded	2000
Employees at IPO	10

IPO News for Galmed Pharmaceuticals

Galmed Pharmaceuticals (GLMD) Performance